Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
NCT06685185Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0363-1063 in type 1 diabetes mellitus (T1D) (7 arms), sponsored by Novo Nordisk. Primary endpoints: Number of adverse events, Apparent serum clearance up to 7 days and 1 more. Started Nov 2024; status: completed.
02
Drugs
NNC0363-1063
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06685185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685185.